Fulgent Cash vs Property Plant And Equipment Net Analysis

FLGT Stock  USD 22.48  0.73  3.36%   
Fulgent Genetics financial indicator trend analysis is much more than just examining Fulgent Genetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulgent Genetics is a good investment. Please check the relationship between Fulgent Genetics Cash and its Property Plant And Equipment Net accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Cash vs Property Plant And Equipment Net

Cash vs Property Plant And Equipment Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulgent Genetics Cash account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have strong relationship.
The correlation between Fulgent Genetics' Cash and Property Plant And Equipment Net is 0.77. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of Fulgent Genetics, assuming nothing else is changed. The correlation between historical values of Fulgent Genetics' Cash and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Fulgent Genetics are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Cash i.e., Fulgent Genetics' Cash and Property Plant And Equipment Net go up and down completely randomly.

Correlation Coefficient

0.77
Relationship DirectionPositive 
Relationship StrengthSignificant

Cash

Cash refers to the most liquid asset of Fulgent Genetics, which is listed under current asset account on Fulgent Genetics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Fulgent Genetics customers. The amounts must be unrestricted with restricted cash listed in a different Fulgent Genetics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.
Most indicators from Fulgent Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Discontinued Operations is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 93.4 M in 2024, whereas Tax Provision is likely to drop slightly above 2.5 M in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit777.1M366.9M96.6M179.1M
Total Revenue992.6M619.0M289.2M266.7M

Fulgent Genetics fundamental ratios Correlations

0.920.851.00.990.98-0.870.980.850.870.82-0.150.430.790.660.930.660.510.810.960.970.830.96-0.59-0.590.81
0.920.930.910.90.9-0.780.850.940.810.74-0.330.240.870.80.860.80.360.70.980.870.920.88-0.58-0.580.72
0.850.930.840.830.76-0.840.781.00.910.48-0.30.480.830.910.880.90.070.830.890.720.910.72-0.56-0.560.47
1.00.910.840.990.98-0.870.990.840.860.81-0.150.430.790.650.930.640.520.820.950.970.830.96-0.59-0.590.81
0.990.90.830.990.98-0.910.970.820.880.81-0.040.470.720.680.920.680.480.840.960.960.770.96-0.6-0.60.79
0.980.90.760.980.98-0.790.960.770.770.91-0.140.270.760.570.880.580.640.710.951.00.791.0-0.59-0.590.9
-0.87-0.78-0.84-0.87-0.91-0.79-0.83-0.82-0.98-0.51-0.19-0.77-0.53-0.82-0.87-0.82-0.09-0.97-0.85-0.76-0.63-0.740.560.56-0.46
0.980.850.780.990.970.96-0.830.770.820.81-0.170.420.780.550.880.550.580.780.890.960.790.95-0.48-0.480.83
0.850.941.00.840.820.77-0.820.770.890.5-0.320.430.850.90.890.90.10.810.890.730.920.73-0.6-0.60.49
0.870.810.910.860.880.77-0.980.820.890.470.070.740.630.850.910.850.060.980.850.740.720.72-0.57-0.570.43
0.820.740.480.810.810.91-0.510.810.50.47-0.16-0.080.640.260.650.270.860.370.80.930.620.94-0.44-0.440.99
-0.15-0.33-0.3-0.15-0.04-0.14-0.19-0.17-0.320.07-0.160.45-0.69-0.02-0.180.0-0.270.15-0.14-0.17-0.6-0.170.130.13-0.28
0.430.240.480.430.470.27-0.770.420.430.74-0.080.450.050.560.50.54-0.360.840.330.240.150.21-0.24-0.24-0.11
0.790.870.830.790.720.76-0.530.780.850.630.64-0.690.050.550.810.550.460.530.780.770.990.77-0.53-0.530.7
0.660.80.910.650.680.57-0.820.550.90.850.26-0.020.560.550.711.0-0.240.790.780.50.680.51-0.5-0.50.19
0.930.860.880.930.920.88-0.870.880.890.910.65-0.180.50.810.710.70.340.880.880.860.850.85-0.78-0.780.65
0.660.80.90.640.680.58-0.820.550.90.850.270.00.540.551.00.7-0.230.780.790.50.680.52-0.48-0.480.2
0.510.360.070.520.480.64-0.090.580.10.060.86-0.27-0.360.46-0.240.34-0.230.00.410.70.360.7-0.22-0.220.9
0.810.70.830.820.840.71-0.970.780.810.980.370.150.840.530.790.880.780.00.760.670.620.65-0.6-0.60.35
0.960.980.890.950.960.95-0.850.890.890.850.8-0.140.330.780.780.880.790.410.760.920.840.93-0.59-0.590.76
0.970.870.720.970.961.0-0.760.960.730.740.93-0.170.240.770.50.860.50.70.670.920.781.0-0.56-0.560.93
0.830.920.910.830.770.79-0.630.790.920.720.62-0.60.150.990.680.850.680.360.620.840.780.78-0.57-0.570.66
0.960.880.720.960.961.0-0.740.950.730.720.94-0.170.210.770.510.850.520.70.650.931.00.78-0.57-0.570.93
-0.59-0.58-0.56-0.59-0.6-0.590.56-0.48-0.6-0.57-0.440.13-0.24-0.53-0.5-0.78-0.48-0.22-0.6-0.59-0.56-0.57-0.571.0-0.41
-0.59-0.58-0.56-0.59-0.6-0.590.56-0.48-0.6-0.57-0.440.13-0.24-0.53-0.5-0.78-0.48-0.22-0.6-0.59-0.56-0.57-0.571.0-0.41
0.810.720.470.810.790.9-0.460.830.490.430.99-0.28-0.110.70.190.650.20.90.350.760.930.660.93-0.41-0.41
Click cells to compare fundamentals

Fulgent Genetics Account Relationship Matchups

Fulgent Genetics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets88.8M700.5M1.3B1.4B1.3B1.3B
Other Current Liab3.6M62.7M36.7M58.4M49.1M51.6M
Total Current Liabilities6.0M131.1M112.8M116.2M73.0M49.4M
Total Stockholder Equity82.8M569.4M1.2B1.3B1.1B1.2B
Net Tangible Assets82.8M569.4M1.2B973.0M1.1B1.2B
Property Plant And Equipment Net6.0M40.2M62.3M81.4M94.3M99.0M
Net Debt(9.3M)(71.6M)(164.9M)(58.9M)(82.6M)(78.4M)
Retained Earnings(63.4M)150.9M657.6M801M633.2M664.8M
Accounts Payable1.6M26.5M20.5M23.1M15.4M10.3M
Cash12.0M87.4M164.9M79.5M97.5M50.9M
Non Current Assets Total12.0M84.7M62.3M480.4M765.3M803.5M
Non Currrent Assets Other(36.8M)(88.0M)142.0M(287.4M)32.0M33.6M
Other Assets251K44.5M912.6M26.6M1.00.95
Cash And Short Term Investments70.2M431.9M164.9M852.9M424.2M227.7M
Net Receivables6.6M183.9M138.9M52.7M57.4M50.2M
Common Stock Shares Outstanding18.7M24.1M31.2M31.0M29.8M23.5M
Liabilities And Stockholders Equity88.8M700.5M1.3B1.4B1.3B1.3B
Inventory277K16.5M12.2M4.3M5.8M4.4M
Other Current Assets277K(16.5M)(12.2M)22.2M26.2M27.6M
Other Stockholder Equity146.1M418.1M1.2B477.4M481.3M332.8M
Total Liab6.0M131.1M112.8M116.2M139.8M146.8M
Property Plant And Equipment Gross8.6M41.0M81.9M124.6M135.1M141.9M
Total Current Assets76.8M615.7M303.8M905.6M507.8M280.8M
Accumulated Other Comprehensive Income146K438K(759K)(20.9M)1.2M1.3M
Property Plant Equipment8.6M40.2M62.3M98.9M113.8M119.4M
Retained Earnings Total Equity(63.0M)(63.4M)150.9M657.6M756.2M794.0M
Short Term Investments58.3M344.4M770.7M773.4M326.7M326.9M
Non Current Liabilities Total2.3M959K7.5M28.1M66.8M70.1M
Capital Surpluse114.2M146.1M418.1M501.9M577.2M606.1M
Long Term Investments42.8M132.5M507.0M339.0M444.0M466.2M
Non Current Liabilities Other2.3M959K7.5M28.1M11.0M6.8M
Net Invested Capital82.8M584.4M1.2B1.3B1.1B688.3M
Net Working Capital33.4M393.5M961.6M539.8M434.8M381.8M
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fulgent Genetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fulgent Genetics' short interest history, or implied volatility extrapolated from Fulgent Genetics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Fulgent Genetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Fulgent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Fulgent Genetics Stock. Highlighted below are key reports to facilitate an investment decision about Fulgent Genetics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.
Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Fulgent Stock analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.99)
Earnings Share
(5.56)
Revenue Per Share
9.635
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.03)
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.